RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...
Discover IMRX’s innovative cancer drug atebimetinib and upcoming milestones. Learn about trial results, financial outlook, ...
Retrospective review of FOLFIRINOX in local advanced pancreatic cancer: Single institution experience.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback